CME in Minutes: Education in Primary Care

Please visit answersincme.com/ZSN860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Wanda Phipatanakul, MD, MS. In this activity, an expert in pediatric asthma discusses how to identify type 2 inflammation and tailor biologic therapy for pediatric patients with asthma. Upon completion of this activity, participants should be better able to: Identify the impact of type 2 inflammation on lung function in pediatric patients with asthma; Recognize best practices for incorporating biologics into the treatment of type 2 inflammatory pediatric asthma; and Outline the role of multidisciplinary teams in optimizing outcomes for pediatric patients with type 2 inflammatory asthma. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/JJK860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Rajsekar (Raj) Rajaraman, MD, MS. In this activity, an expert in pediatric neurology discusses the diagnosis and management of CDKL5 deficiency disorder. Upon completion of this activity, participants should be better able to: Describe key clinical characteristics that contribute to the burden of CDKL5 deficiency disorder (CDD); Evaluate the role of timely diagnosis in influencing care decisions for individuals with CDD; and Outline therapeutic approaches for managing seizures associated with CDD.

Please visit answersincme.com/860/104092969-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Beth Faiman, PhD, MSN, APN-BC, TCTCN, AOCN, FAAN, FAPO; and Jesus Berdeja, MD. In this activity, experts in hematology-oncology discuss the evolving role of cereblon E3 ligase modulators (CELMoDs) in patients with relapsed/refractory multiple myeloma (RRMM). Upon completion of this activity, participants should be better able to: Identify the role of CELMoDs in the treatment of patients with RRMM. Utilize evidence-based practical strategies for the management of key adverse events associated with CELMoDs in patients with RRMM. Apply key considerations to support the integration of CELMoDs into the treatment paradigm for patients with RRMM.

Please visit answersincme.com/860/CME-26-207477-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Vallerie V. McLaughlin, MD; and Richard Channick, MD. In this activity, experts in pulmonary arterial hypertension (PAH) discuss strategies for personalized risk-based intensification of therapy for patients with PAH. Upon completion of this activity, participants should be better able to: Describe the rationale for risk-based treatment intensification strategies in patients with PAH. Identify clinical indicators warranting escalation of therapy in patients with intermediate- or high-risk PAH. Outline an evidence-based, personalized approach to integrating novel add-on therapies into treatment plans for patients with PAH. undefined In this activity, experts in pulmonary arterial hypertension (PAH) discuss strategies for personalized risk-based intensification of therapy for patients with PAH.

Please visit answersincme.com/860/014832-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Anne E. O'Donnell, MD; andPatrick Flume, MD. In this activity, experts in bronchiectasis discuss best practices for identifying, diagnosing, and treating CF and non-CF bronchiectasis. Upon completion of this activity, participants should be better able to:Distinguish between underlying causes of bronchiectasis that provide the rationale for targeting neutrophil inflammation. Outline recommended multidisciplinary strategies to promptly recognize and diagnose bronchiectasis. Describe the design and eligibility criteria of ongoing trials evaluating neutrophil-targeted therapies for bronchiectasis. This session is supported by Boehringer Ingelheim Pharmaceuticals, Inc. Exhibitors and supporters of NACFC include manufacturers of CF drugs, medical device companies, pharmacies, hospitals, and other related organizations. The Cystic Fibrosis Foundation does not support nor endorse the products or services of NACFC 2026 exhibitors and supporters.